10.44
+3.16%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Satellos Bioscience
Its shares trade on Toronto Stock Exchange under the ticker MSCL.TO. It has been listed since 1 December 2006. In the fiscal year to 31 December 2019, it reported revenue of $34,537 and a net loss of $2.7m. At that date it held total assets of $1.5m and shareholders' equity of $564,430.
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Dec 2006
- Employees
- 3
- Website
- satellos.com ↗
Leadership
Pay as last reported
- Mr. Geoff MackayIndependent Chairman of the Board, since 2018C$114,393
- Mr. Frank GleesonPresident, Chief Executive Officer, Director, since 2021C$750,000
- Ms. Elizabeth WilliamsChief Financial Officer, since 2023C$525,000
- Ms. Courtney WellsSenior Vice President - Clinical Development Operations
- Dr. Philip LambertChief Scientific OfficerC$757,581
- Dr. Wildon FarwellChief Medical Officer
- Dr. Michael RudnickiChief Discovery OfficerC$98,000
- Dr. Selwyn HoDirector
- Prof. Dr. Iris Loew-FriedrichDirector
- Mr. Franklin BergerIndependent DirectorC$69,607
- Mr. Brian BloomIndependent Director
- Ms. Stephanie BrownIndependent DirectorC$12,650
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MyoReGenX platform enables mapping muscle repair pathways for drug development.
- Oral Amp B Delivery System is a patented oral transport technology for drug delivery.
- Bertilimumab targets eotaxin-1 for treating allergic and inflammatory conditions.
Weaknesses
- 3 full-time employees limit operational capacity and resource availability.
- IPO on 1 December 2006 indicates limited market presence and growth potential.
- Duchenne muscular dystrophy focus narrows therapeutic application scope.
Opportunities
- MyoReGenX platform can expand to treat other degenerative muscle conditions beyond Duchenne.
- iCo portfolio includes Oral Amp B Delivery System for broader drug delivery applications.
- Bertilimumab potential in allergic and inflammatory conditions offers market expansion.
Threats
- Degenerative muscle conditions competition from established biotechnology firms.
- Duchenne muscular dystrophy treatment market has high regulatory hurdles.
- Small molecule drug candidate development faces clinical trial challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.